LONDON, Feb. 26, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference on Monday, 3 March, 2014 at 3:30 p.m. ET. The conference will be held at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com . A replay will be available soon after the live presentation.
About GW Pharmaceuticals plcFounded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type‑2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com . Enquiries:
|GW Pharmaceuticals plc||(Today) + 44 20 7831 3113|
|Justin Gover, Chief Executive Officer||(Thereafter) + 44 1980 557000|
|Stephen Schultz, VP Investor Relations (US)||+ 1 401 500 6570|
|FTI Consulting (Media Enquiries)|
|Ben Atwell / Simon Conway / John Dineen (UK)||+ 44 20 7831 3113|
|Robert Stanislaro (US)||+1 212 850 5657|
|Trout Group, LLC (US investor relations)|
|Todd James / Chad Rubin||+1 646 378 2900|
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts